NCT06597422View on ClinicalTrials.gov

A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 20, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

May 31, 2025

Conditions
Neurotrophic Keratitis
Interventions
DRUG

STSP-0902 ophthalmic solution

Eye drop, single dose

DRUG

STSP-0902 Placebo

Eye drop, single dose

DRUG

STSP-0902 ophthalmic solution

Eye drop, three times daily for a total of 8 days

DRUG

STSP-0902 ophthalmic solution

Eye drop, six times daily for a total of 8 days

DRUG

STSP-0902 Placebo

Eye drop, multiple doses

DRUG

STSP-0902 ophthalmic solution

Eye drop, single dose, tear samples will be collected

Trial Locations (1)

100005

Beijing Tongren Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT06597422 - A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects | Biotech Hunter | Biotech Hunter